

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, March 17, 2022
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/99337766415 Webinar ID: 993 3776 6415 Password: 425341	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 993 3776 6415 Passcode: 425341

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of November 2021 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Qulipta™ (Anti-Migraine: CGRP Inhibitors)
 - ii. Lybalvi™ (Second-Generation Antipsychotics)
 - iii. Winlevi® (Topical Acne Agents)
 - iv. Azstarys™ (Stimulants and Related Agents)
 - v. Bylvay™ (Bile Salts)
 - vi. Livmarli™ (Bile Salts)
 - vii. Opzelura™ (Immunomodulators, Atopic Dermatitis)
 - viii. Rezurock™ (Immunosuppressants)
 - ix. Tyrvaya™ (Ophthalmic Immunomodulators)
 - x. Skytrofa™ (Growth Hormones)
 - xi. Livtency™ (Non-PDL)
 - xii. Exkivity™ (Non-PDL: Oral Oncology, Lung)
 - xiii. Scemblix® (Non-PDL: Oral Oncology)
 - xiv. Welireg® (Non-PDL: Oral Oncology)
 - b. Existing products to be reviewed as single products:
 - i. Tukysa® (Non-PDL: Oral Oncology, Breast)
 - ii. Pemazyre™ (Non-PDL: Oral Oncology)
 - iii. Qinlock™ (Non-PDL: Oral Oncology)
- I. Therapeutic Classes with Recommended Changes**
 - a. Antibiotics: Gastrointestinal (GI)
 - b. Antibiotics: Vaginal
 - c. Antiretrovirals: HIV/AIDS

d. Antibiotics: Oxazolidinones

V. Consent Agenda

a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none">• Antibiotics: Cephalosporins 1st Generation• Antibiotics: Cephalosporins 2nd Generation• Antibiotics: Cephalosporins 3rd Generation• Antibiotics: Inhaled• Antibiotics: Macrolides/Ketolides• Antibiotics: Penicillins• Antibiotics: Pleuromutilins• Antibiotics: Quinolones• Antibiotics: Sulfonamides, Folate Antagonists• Antibiotics: Tetracyclines• Antifungals: Oral• Anti-Infectives: Hepatitis B• Antivirals: Herpes	<ul style="list-style-type: none">• Antivirals: Influenza• Beta Agonists: Combination Products• COPD Agents• Hepatitis C: Direct-Acting Antiviral Agents• Hepatitis C: Interferons• Hepatitis C: Ribavirins• Inhaled Corticosteroids• Intranasal Antihistamines and Anticholinergics• Intranasal Corticosteroids• Leukotriene Modifiers• Minimally Sedating Antihistamines• Self-Injectable Epinephrine
---	--

V. Adjournment

a. Schedule of Upcoming Meetings

i. **May 19, 2022**

ii. **July 21, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.